Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hematologic Malignancy Reports
Erschienen in: Current Hematologic Malignancy Reports 6/2017

24.10.2017 | Invited Commentary

Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond

verfasst von: Naveen Pemmaraju

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Excerpt

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a historically rare hematologic malignancy with poor overall outcomes, a challenging pathologic and clinical presentation, and no consensus therapeutic approach [1]. After decades of changing nomenclature (e.g., CD4+CD56+ hematodermic tumor, blastic NK cell lymphoma), the WHO ultimately solidified the name “BPDCN” and placed it under “Acute myeloid leukemia (AML) and related family of neoplasms” in 2008 [2]. With increasing understanding of BPDCN, further recognition of its distinct clinical presentation and course, and evolving molecular insights, the disease has now been designated as its own separate category under myeloid malignancies in the latest WHO re-classification schema [3]. …
Literatur
1.
Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2016;14:220–2.PubMed
2.
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRefPubMed
3.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRefPubMed
4.
Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:1006–12.CrossRefPubMed
5.
Pemmaraju N, Thomas D, Kantarjian HM, et al. Analysis of outcomes of patients with blastic plasmacytoid dendritic cell neoplasm. ASH Annual Meeting Abstracts. 2012;120:3554.
6.
Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174:188–202.CrossRefPubMed
7.
Brunetti L, Di Battista V, Venanzi A, et al. Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin. Leukemia. 2017;31:1238–40.CrossRefPubMed
8.
Aoki T, Suzuki R, Kuwatsuka Y, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125:3559–62.CrossRefPubMed
9.
Roos-Weil D, Dietrich S, Boumendil A, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121:440–6.CrossRefPubMed
10.
Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777–84.CrossRefPubMed
11.
12.
Frankel A. Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies. ASCO Annual Meeting 2013. J Clin Oncol (Meeting Abstracts). 2013;31(15_suppl):7029.
13.
Pemmaraju N et al. Results from phase 2 trial ongoing expansion stage of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood (ASH abstract #4245, Dec 2016) 2016.
14.
Pemmaraju NLA, Sweet KL, Stein A, Sumithira V, Blum WG. Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): lead-in completed, expansion stage ongoing. J Clin Oncol 2016; 34 (suppl; abstr 7006).
15.
Cai T, Galetto R, Gouble A, et al. Pre-clinical studies of anti-CD123 CAR-T cells for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood. 2016;128:4039.CrossRef
16.
Mardiros A, Dos Santos C, McDonald T, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122:3138–48.CrossRefPubMedPubMedCentral
17.
Nievergall E, Ramshaw HS, Yong AS, et al. Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014;123:1218–28.CrossRefPubMed
18.
Bonifant CL, Szoor A, Torres D, et al. CD123-engager T cells as a novel immunotherapeutic for acute myeloid leukemia. Mol Ther. 2016;24:1615–26.CrossRefPubMedPubMedCentral
19.
Tasian SK, Kenderian SS, Shen F, et al. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood. 2017;129:2395–407.CrossRefPubMed
20.
Seung Y, Chu EP, Chen H, Phung S, Chan EW, Endo NA, et al. Immunotherapy with long-lived anti-CD123 × anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human AML cell lines and of CD123+ cells in monkeys: a potential therapy for acute myelogenous leukemia. Blood (ASH abstract). 2014;124:2316.CrossRef
21.
Al-Hussaini M, Rettig MP, Ritchey JK, et al. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. Blood. 2016;127:122–31.CrossRefPubMedPubMedCentral
22.
Sapienza MR, Fabio F, Claudio A, et al. Molecular profiling of blastic plasmacytoid dendritic CELL neoplasm reveals a unique pattern and suggests selective sensitivity to NF-KB pathway inhibition. Blood. 2013;122:2502.
23.
24.
Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–8.CrossRefPubMed
25.
Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia.
26.
Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer discovery. 2016;6:1106–17.CrossRefPubMedPubMedCentral
27.
Montero J, Stephansky J, Cai T, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discovery. 2017;7:156–64.CrossRefPubMed
28.
29.
30.
31.
Ott CJ, Kopp N, Bird L, et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012;120:2843–52.CrossRefPubMedPubMedCentral
32.
Emadali A, Hoghoughi N, Duley S, et al. Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms. Blood. 2016;127:3040–53.CrossRefPubMedPubMedCentral
33.
Ceribelli M, Hou ZE, Kelly PN, et al. A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell. 2016;30:764–78.CrossRefPubMedPubMedCentral
Metadaten
Titel
Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond
verfasst von
Naveen Pemmaraju
Publikationsdatum
24.10.2017
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 6/2017
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-017-0425-7

Weitere Artikel der Ausgabe 6/2017

Current Hematologic Malignancy Reports 6/2017 Zur Ausgabe

Acute Myeloid Leukemias (H Erba, Section Editor)

The Prognostic Significance of Measurable (“Minimal”) Residual Disease in Acute Myeloid Leukemia

Acute Myeloid Leukemias (H Erba, Section Editor)

Measurement of Residual Disease in Acute Myeloid Leukemia

Acute Myeloid Leukemias (H Erba, Section Editor)

Methods of Detection of Measurable Residual Disease in AML

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Social Media in Hematology in 2017: Dystopia, Utopia, or Somewhere In-between?

Invited Commentary

Prognostication and Initiation of Therapy in Polycythemia Vera: Do We Have it Right?

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Using Social Media at National Meetings in Hematology—Optimal Use, Tips, Strategies, and Limitations

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen